Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TP53-target gene 3 protein (TP53TG3E) is one of several paralogs induced by the action of the tumor suppressor gene TP53 (which encodes p53), a key transcription factor in cell cycle regulation, DNA damage response, and apoptosis. The TP53TG3 gene family (including TP53TG3A, B, C, D, E, F) encodes small proteins with no well-characterized domains, motifs, or described molecular function. There is no experimental data linking TP53TG3E to specific biological pathways, molecular interactions, or disease mechanisms, and it is not considered a classical therapeutic target such as a receptor, enzyme, transporter, or transcription factor[4]. Because of the lack of functional annotation, absence from disease association studies, and lack of evidence of drug interactions, TP53TG3E is not recognized as a standard therapeutic target or a biomarker, and there is insufficient information for further pharmacological evaluation. If you require information about p53 itself as a target (the TP53 gene/protein), extensive data is available, but for "TP53 target 3 family member E," the evidence base is very limited.
Not available
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TP53-target gene 3 protein (TP53TG3E).